Gerald Commissiong Email and Phone Number
Gerald Commissiong work email
- Valid
- Valid
- Valid
- Valid
Gerald Commissiong personal email
- Valid
As a managing partner at Fortitude Advisors LLC, I provide executive and financial advisory services to biotechnology and emerging growth companies, leveraging my 12.5+ years of experience as the president and executive chairman of Amarantus Bioscience Holdings, Inc., a biopharmaceutical company focused on developing novel therapies and diagnostics for unmet medical needs in COVID-19, pediatric severe burns, blindness, multiple sclerosis, Parkinson's disease and Alzheimer's disease.I also have four years of experience as the former CEO of Todos Medical Ltd., an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers and neurodegenerative disorders, such as Alzheimer's disease. I led the company's strategic planning, business development, and corporate development, securing multiple partnerships, acquisitions, and financing deals. My mission is to build and grow biotechnology companies that can deliver innovative and life-changing solutions for patients and society.
-
Chief Business OfficerOs Therapies May 2024 - PresentNew York, Ny, Us
-
President & Executive ChairmanAmarantus Bioscience Holdings, Inc. Oct 2011 - Present
-
Chief Executive OfficerTodos Medical Jan 2020 - Jan 2024New York, Ny, UsTodos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease.For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com -
Board MemberAvant Diagnostics, Inc. May 2016 - Aug 2017Corporate strategy and acquisitions -
Chief Operating OfficerAmarantus Biosciences, Inc. May 2011 - Oct 2011
-
Co-Founder & CboAmarantus Therapeutics, Inc. Jan 2008 - Jun 2011Amarantus Therapeutics, Inc., formerly known as CNS Protein Therapeutics, is a privately-held biotechnology company that is developing first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company’s most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson’s disease and Myocardial Infarction. Amarantus is currently incubating at the Parkinson’s Institute, www.amarantustherapeutics.comMedia Contacts:Erik Clausen or Kena HudsonCollege Hill, Inc. for Amarantus Therapeutics, Inc.415-230-5385Erik.Clausen@
-
Chief Business OfficerCns Protein Therapeutics, Inc. Jan 2008 - Oct 2009Sunnyvale, Ca, UsCNS Protein Therapeutics is a pre-clinical stage biotechnology company developing biologics for the treatment of Parkinson's and Cardiovascular disease.Gerald Commissiong is responsible for all business development activities. -
Founder & CeoCns Protein Therapeutics, Inc. Dec 2007 - Jan 2008Sunnyvale, Ca, UsCNS Protein Therapeutics is a biotech company focused on the clinical development of neurotrophic factors to treat of Parkinson's disease.
-
PlayerCalgary Stampeders May 2007 - Nov 2007Fullback for the Calgary Stampeders.
-
Interim-CeoNeurotrophics Inc. Oct 2006 - Nov 2007Neurotrophics Inc. is seeking to develop astrocytes as a potential source of drugs to treat neurodegenerative disease.
-
Web ConsultantMaxim Integrated Products Jul 2005 - Jun 2006San Jose, Ca, UsI assisted in the creation and implementation of recommendations designed to improve website interface.
Gerald Commissiong Skills
Gerald Commissiong Education Details
-
Stanford UniversityManagement Science & Engineering -
Saint Michael'S College SchoolHigh School Diploma
-
Collège Notre-DameHigh School Diploma
Frequently Asked Questions about Gerald Commissiong
What company does Gerald Commissiong work for?
Gerald Commissiong works for Os Therapies
What is Gerald Commissiong's role at the current company?
Gerald Commissiong's current role is Chief Business Officer at OS Therapies (NYSE: OSTX).
What is Gerald Commissiong's email address?
Gerald Commissiong's email address is gc****@****ail.com
What schools did Gerald Commissiong attend?
Gerald Commissiong attended Stanford University, Saint Michael's College School, Collège Notre-Dame.
What skills is Gerald Commissiong known for?
Gerald Commissiong has skills like Biotechnology, Entrepreneurship, Business Development, Start Ups, Corporate Development, Venture Capital, Strategic Planning, Mergers And Acquisitions, Technology Transfer, Strategic Partnerships, Clinical Development, Protein Chemistry.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial